{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T13:58:30Z","timestamp":1780581510671,"version":"3.54.1"},"reference-count":37,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2003,12,1]],"date-time":"2003-12-01T00:00:00Z","timestamp":1070236800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Psychopharmacol"],"published-print":{"date-parts":[[2003,12]]},"abstract":"<jats:p>The study aimed to discover whether acamprosate reduces the severity of relapse for those patients undergoing abstinence\u2013orientated treatment who are unable to abstain completely. Data on patients\u2019 alcohol consumption from 15 placebo-controlled treatment studies (n = 3309) were examined to test whether, at a given time point, patients who have taken one or more drinks since the last assessment (\u2018relapsers\u2019, n = 1010) take alcohol on fewer days, report lower average number of drinks per day, and consume less alcohol in total with acamprosate compared to placebo. These studies had varying duration (90 days, 180 days and 360 days). There were four dates that were common to some studies (days 30, 90, 180 and 360). Among relapsers, acamprosate was significantly associated with less quantity (Q) and frequency (F) of drinking compared to placebo in each of the four follow-up periods (p &lt; 0.001). The differences were most marked for the product Q \u00d7 F (overall weekly consumption). For each period, there were fewer who were drinking an average of five or more drinks per day in the acamprosate compared to the placebo groups. Acamprosate helps reduce the severity of relapse in patients undergoing abstinence-orientated treatment.<\/jats:p>","DOI":"10.1177\/0269881103174017","type":"journal-article","created":{"date-parts":[[2004,4,21]],"date-time":"2004-04-21T21:27:18Z","timestamp":1082582838000},"page":"397-402","source":"Crossref","is-referenced-by-count":48,"title":["Does Acamprosate Improve Reduction of Drinking As Well As Aiding Abstinence?"],"prefix":"10.1177","volume":"17","author":[{"given":"Jonathan","family":"Chick","sequence":"first","affiliation":[{"name":"Department of Psychiatry, University of Edinburgh, Royal Edinburgh                         Hospital Edinburgh UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Lehert","sequence":"additional","affiliation":[{"name":"Department of Statistics University of Mons Mons Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Landron","sequence":"additional","affiliation":[{"name":"Merck-Sant\u00e9, Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2003,12,1]]},"reference":[{"key":"atypb1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1530-0277.1998.tb03872.x"},{"key":"atypb2","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1176\/ajp.156.11.1758","volume":"156","author":"Anton R F","year":"1999","journal-title":"Am J Psychiatry"},{"key":"atypb3","doi-asserted-by":"publisher","DOI":"10.15288\/jsa.2000.61.55"},{"key":"atypb4","first-page":"149","volume":"18","author":"Barrias J A","year":"1997","journal-title":"Psyquiatr Clin"},{"key":"atypb5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1530-0277.1998.tb04295.x"},{"key":"atypb6","volume-title":"Randomised controlled trial of acamprosate versus placebo in Swedish alcoholics","author":"Borg S","year":"2003"},{"key":"atypb7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1530-0277.1998.tb03925.x"},{"key":"atypb8","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1093\/alcalc\/35.6.587","volume":"35","author":"Chick J","year":"2000","journal-title":"Alcohol Alcohol"},{"key":"atypb9","doi-asserted-by":"publisher","DOI":"10.1093\/alcalc\/35.2.176"},{"key":"atypb10","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-0082(99)00031-3"},{"key":"atypb11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1530-0277.1999.tb04099.x"},{"key":"atypb12","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(86)90046-2"},{"key":"atypb13","doi-asserted-by":"publisher","DOI":"10.1017\/CBO9780511569654"},{"key":"atypb14","doi-asserted-by":"publisher","DOI":"10.15288\/jsa.1978.39.466"},{"key":"atypb15","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.14.1318"},{"key":"atypb16","doi-asserted-by":"publisher","DOI":"10.1159\/000259166"},{"key":"atypb17","doi-asserted-by":"publisher","DOI":"10.1093\/alcalc\/36.5.413"},{"key":"atypb18","doi-asserted-by":"publisher","DOI":"10.3109\/10826088309027359"},{"key":"atypb19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1530-0277.2001.tb02356.x"},{"key":"atypb20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1530-0277.2002.tb02578.x"},{"key":"atypb21","first-page":"182","volume":"50","author":"Ladewig D","year":"1993","journal-title":"Therapeutische Umschau"},{"key":"atypb22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.1995.tb01088.x"},{"key":"atypb23","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852900012827"},{"key":"atypb24","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1992.01820110045007"},{"key":"atypb25","first-page":"239","volume":"30","author":"Paille M","year":"1995","journal-title":"Alcohol Alcohol"},{"key":"atypb26","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4612-2878-3_44"},{"key":"atypb27","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.171.1.73"},{"key":"atypb28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.1997.tb02873.x"},{"key":"atypb29","first-page":"65","volume":"51","author":"Roussaux J-P","year":"1996","journal-title":"J Pharm Belgique"},{"key":"atypb30","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1996.01830080023006"},{"key":"atypb31","doi-asserted-by":"publisher","DOI":"10.2307\/2348636"},{"key":"atypb32","unstructured":"Slattery J, Chick J, Cochrane M, Craig J, Godfrey C, Kohli, H, MacPherson K, Parrot                 S, Quinn S, Tochel C, Watson H (2003) Prevention of relapse in alcohol dependence.                 Health Technology Assessment Report 3, Glasgow, Health Technology Board of Scotland;                 www.htbs.co.uk"},{"key":"atypb33","first-page":"39","volume":"305","author":"Spanagel R","year":"1996","journal-title":"Effects on alcohol intake following alcohol deprivation in the rat. Eur J Pharmacol"},{"key":"atypb34","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.151.10.1463"},{"key":"atypb35","doi-asserted-by":"publisher","DOI":"10.1093\/alcalc\/35.2.202"},{"key":"atypb36","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.152.4.613"},{"key":"atypb37","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)91682-7"}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0269881103174017","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0269881103174017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:08:50Z","timestamp":1777507730000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0269881103174017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,12]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2003,12]]}},"alternative-id":["10.1177\/0269881103174017"],"URL":"https:\/\/doi.org\/10.1177\/0269881103174017","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,12]]}}}